Skip to main content

1UO FDA Approval Status

FDA Approved: No
Brand name: 1UO
Generic name: uracil
Dosage form: Topical
Previous Name: Xyfid
Company: Cahaba Pharmaceuticals
Treatment for: Hand-Foot Syndrome

1UO (uracil) is a first-in-class dihydropyrimidine dehydrogenase (DPD) inhibitor in development for the treatment of Hand-Foot Syndrome (HFS), also known as Palmar-Plantar Erythrodysesthesia.

Development timeline for 1UO

Sep 10, 2008VioQuest Pharmaceuticals Receives 510(k) Response from FDA for Xyfid
Jul  1, 2008VioQuest Pharmaceuticals Submits 510(k) Application to FDA for Xyfid, a Novel Topical Agent for the Treatment of Various Skin Disorders

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.